NCT06184568已完成3 期
A Multicenter, Randomized, Open-label Phase 3 Study Comparing the Efficacy and Safety of IBI362 Versus Semaglutide in Chinese Participants With Early Type 2 Diabetes and Obesity (DREAMS-3)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 349
- 试验地点
- 1
- 主要终点
- Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss
研究概览
简要总结
This is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D subjects. Subjects will be randomly assigned to IBI362 6 mg and Semalgutide 1 mg groups for 32 weeks (active-controlled treatment period). In the extension period, participants originally on mazdutide were assigned to continue for an additional 24 weeks with mazdutide 9 mg or 6 mg based on whether they achieved the weight-loss target. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 32-week active-controlled treatment period, a 24 week extension period and a 4-week drug withdrawal safety follow-up period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, age 18 years or older at the time of signing informed consent
- •T2D was diagnosed according to WHO standards in 1999(≤5 years)
- •The blood glucose was not well controlled after diet and exercise with/without sable metformin(≥1500mg/day，no more than 2550mg/day) within 3 months before screening, and the local laboratory tested 7.5% ≤ HbA1c ≤9.5% during screening
- •Have a BMI ≥28 kg/m2
排除标准
- •Subjects who the investigator thinks may be allergic to the components in the study drug or similar drugs
- •A self-reported change in body weight above 5% within 3 months before screening
- •Oral hypoglycemic drugs other metformin have been used within 2 months before screening.
- •Previous diagnosis of type 1 diabetes (including adult latent autoimmune diabetes)
- •There are active or untreated malignant tumors within 5 years before screening, or patients are in remission of clinical malignant tumors (except patients with skin basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ or papillary thyroid carcinoma who have no recurrence after surgery)
- •Mental illness existed in the past or at the time of screening, and the researcher thinks it is not suitable to participate in this study
- •Pregnant or lactating women, or men or women who are fertile and unwilling to use contraception throughout the study period
- •The investigator believes that the subject has any other factors that may affect the efficacy or safety evaluation of this study and is not suitable to participate in this study
研究组 & 干预措施
Semaglutide
Active Comparator
干预措施: Semaglutide (Drug)
IBI362
Experimental
干预措施: IBI362 (Drug)
结局指标
主要结局
Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss
时间窗: Week 32
次要结局
- Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥15% weight loss(Week 32)
- Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥5% weight loss(Week 32)
- Proportion of subjects who achieve composite endpoint of HbA1c<6.5% and ≥5%, ≥10% or ≥15% weight loss(Week 32)
- Change from Baseline in HbA1c(Week 32)
- Change in HOMA2-β from baseline(Week 32)
- Change in HOMA2-IR from baseline(Week 32)
- Change in body weight from baseline(Week 32)
- Percent change in body weight from baseline(Week 32)
- Change in waist circumference from baseline(Week 32)
- Change in body mass index (BMI) from baseline(Week 32)
- Proportion of subjects achieving weight loss of ≥ 5%, ≥ 10%, or ≥ 15%(Week 32)
- Proportion of patients achieving 24 kg/m 2≤ BMI < 28 kg/m 2 and 18.5 kg/m 2≤ BMI < 24 kg/m 2(Week 32)
- Change in systolic blood pressure(SBP) and diastolic blood pressure(DBP) from baseline(Week 32)
- Change in lipids [total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG)] from baseline(Week 32)
- Changes in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) from baseline(Week 32)
- Change in serum uric acid from baseline(Week 32)
- Change in quality of life (IWQoL-Lite-CT) from baseline(Week 32)
- Change in quality of life (SF-36 v2) from baseline(Week 32)
- Proportion of subjects achieving HbA1c < 7.0%, ≤ 6.5%, and < 5.7%(Week 32)
- Change in fasting plasma glucose(FPG) from baseline(Week 32)
- Change in 7-point self-monitored blood glucose(SMBG) from baseline(Week 32)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)Non Small Cell Lung CancerNCT06082635Shenzhen TargetRx, Inc.321
已完成
3 期
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell LymphomaMantle Cell LymphomaNCT00722137Millennium Pharmaceuticals, Inc.487
进行中（未招募）
3 期
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaUntreated Chronic Lymphocytic LeukemiaNCT04075292AstraZeneca155
已完成
3 期
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic TherapyGastroEsophageal CancerGastric CancerNCT03813784Jiangsu HengRui Medicine Co., Ltd.885
进行中（未招募）
3 期
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After ProstatectomyProstate CancerNCT04181203UNICANCER490